Has 2020 been a big year for regulatory knockbacks?
An analysis of FDA complete response letters does not reveal a big uptick – but the year is not over yet.
Medtechs that book the most sales per employee face the greatest losses
Welcome to the calm before the Covid-19 storm.
Curevac rides the Covid wave
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
Philips spends big in-house while Becton favours buying
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
It’s official: “pipeline in a product” is a thing
Big pharma pipelines are getting smaller, but novel medicines are being tested in more indications than ever before, a new analysis finds.
A baptism of fire for listing medtechs
Medtechs going public in 2020 raised a decent amount of cash, but have had a turbulent time of it since.
Medtech venture investors live up to their name
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
Biopharma takeovers show quantity, if not quality
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
